Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 129-134

  Yabe, Hiroki ^a   Tsukahara, Tomohide ^b   Kawaguchi, Satoshi ^b   Wada, Takuro ^b   Sato, Noriyuki ^b   Morioka, Hideo ^a   Yabe, Hiroo ^a  

^a KEIO UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ewing's sarcoma family of tumor; Immunohistochemistry; Papillomavirus binding factor; Prognostic factor; Tumor associated antigen

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBODY; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; LACTATE DEHYDROGENASE; PAPILLOMAVIRUS BINDING FACTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; BONE TUMOR; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ERYTHROCYTE SEDIMENTATION RATE; EWING SARCOMA; FEMALE; GENDER; GENE OVEREXPRESSION; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE TUMOR; TUMOR BIOPSY; TUMOR LOCALIZATION; UNIVARIATE ANALYSIS;

EID: 38849108843     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.129     Document Type: Article

References (32)

1. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA and Juergens H: Ewing's sarcoma family of tumors: current management. Oncologist 11: 503-519, 2006.
2. Miser JS, Krailo MD, Tarbell NJ, et al: Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide - a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 22: 2873-2876, 2004.
3. Bernstein ML, Devidas M, Lafreniere D, et al: Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457 - a report from the Children's Oncology Group. J Clin Oncol 24: 152-159, 2006.
4. Marcove RC, Mike V, Huvos AG, Southam CM and Levin AG: Vaccine trials for osteogenic sarcoma. A preliminary report. CA Cancer J Clin 23: 74-80, 1973.
5. Neff JR and Enneking WF: Adoptive immunotherapy in primary osteosarcoma. An interim report. J Bone Joint Surg Am 57: 145-148, 1975.
6. Dagher R, Long LM, Read EJ, et al: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdo-myosarcoma: an inter-institute NIH study. Med Pediatr Oncol 38: 158-164, 2002.
7. Maki RG: Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 18: 363-368, 2006.
8. Kawaguchi S, Wada T, Tsukahara T, Ida K, Torigoe T, Sato N and Yamashita T: A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transl Med 3: 31, 2005.
9. Tsukahara T, Nabeta Y, Kawaguchi S, et al: Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 64: 5442-5448, 2004.
10. Boeckle S, Pfister H and Steger G: A new cellular factor recognizes E2 binding sites of papillomaviruses which mediate transcriptional repression by E2. Virology 293: 103-117, 2002.
11. Urano F, Umezawa A, Yabe H, Hong W, Yoshida K, Fujinaga K and Hata J: Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis. Jpn J Cancer Res 89: 703-711, 1998.
12. Enneking WF: A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res: 9-24, 1986.
13. Jaffe N, Paed D, Traggis D, Salian S and Cassady JR: Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38: 1925-1930, 1976.
14. Nesbit Jr ME, Gehan EA, Burgert Jr EO, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8: 1664-1674, 1990.
15. Wilbur JR. Sutow WW, Sullivan MP and Gottlieb JA: Chemotherapy of sarcomas. Cancer 36: 765-769, 1975.
16. Rosen G: Current management of Ewing's sarcoma. Prog Clin Cancer 8: 267-282, 1982.
17. Kaneko M, Nishihira H, Mugishima H, et al: Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan. Med Pediatr Oncol 31: 1-7, 1998.
18. Ahmed A, Gilbert-Barness E and Lacson A: Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols. Pediatr Dev Pathol 7: 342-347, 2004.
19. Kawaguchi S, Wada T, Nagoya S, et al: Extraskeletal myxoid chondrosarcoma: a multi-institutional study of 42 cases in Japan. Cancer 97: 1285-1292, 2003.
20. Mackall CL, Berzofsky JA and Helman LJ: Targeting tumor specific translocation in sarcomas in pediatric patients for immunotherapy. Clin Orthop 373: 25-31, 2000.
21. Meyer-Wentrup F, Richter G and Burdach S: Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope. Pediatr Hematol Oncol 22: 297-308, 2005.
22. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, et al: Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 120: 67-74, 2007.
23. Gure AO, Chua R, Williamson B, et al: Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11: 8055-8062, 2005.
24. Kim J, Reber HA, Hines OJ, et al: The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer 118: 2269-2275, 2006.
25. Yoshida N, Abe H, Ohkuri T, et al: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 28: 1089-1098, 2006.
26. Bolli M, Kocher T, Adamina M, et al: Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236: 785-793, 2002.
27. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC and Resnick MB: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 9: 6453-6460, 2003.
28. Kocher T, Zheng M, Bolli M, et al: Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 100: 702-705, 2002.
29. Oberthuer A, Hero B, Spitz R, Berthold F and Fischer M: The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10: 4307-4313, 2004.
30. Sotobori T, Ueda T, Oji Y, et al: Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma. Cancer 106: 2233-2240, 2006.
31. Srivastava A, Fuchs B, Zhang K, et al: High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res 12: 4237-4243, 2006.
32. Sugiyama H: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev Vaccines 4: 503-512, 2005.